DENTSPLY SIRONA (NASDAQ:XRAY) Updates FY 2025 Earnings Guidance

Key Points

• DENTSPLY SIRONA has provided FY 2025 earnings guidance, projecting EPS of $1.800-$2.000 and revenue of $3.6 billion-$3.7 billion, aligning closely with consensus estimates.
• The company’s stock decreased by 2.6% and has a market capitalization of $2.73 billion, with significant volatility observed over the past year.
• DENTSPLY SIRONA recently announced a quarterly dividend of $0.16 per share, reflecting an annualized yield of 4.7% despite a negative dividend payout ratio.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 1.800-2.000 for the period, compared to the consensus EPS estimate of 1.897. The company issued revenue guidance of $3.6 billion-$3.7 billion, compared to the consensus revenue estimate of $3.7 billion.

DENTSPLY SIRONA Stock Performance

XRAY traded down $0.27 during trading hours on Friday, reaching $12.96. The company's stock had a trading volume of 7,388,427 shares, compared to its average volume of 3,709,823. DENTSPLY SIRONA has a 52 week low of $12.16 and a 52 week high of $27.48. The company's 50-day moving average is $15.71 and its 200-day moving average is $15.92. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.76 and a current ratio of 1.69. The firm has a market cap of $2.58 billion, a PE ratio of -2.73, a price-to-earnings-growth ratio of 0.94 and a beta of 0.94.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.02. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%. The firm had revenue of $936.00 million for the quarter, compared to analyst estimates of $929.67 million. During the same period in the prior year, the firm posted $0.49 EPS. The company's revenue for the quarter was down 4.9% on a year-over-year basis. On average, equities analysts forecast that DENTSPLY SIRONA will post 1.84 EPS for the current year.

DENTSPLY SIRONA Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 10th. Stockholders of record on Friday, September 26th will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 4.9%. The ex-dividend date of this dividend is Friday, September 26th. DENTSPLY SIRONA's dividend payout ratio is -14.10%.

Analyst Ratings Changes

Several analysts have recently issued reports on XRAY shares. Wall Street Zen lowered DENTSPLY SIRONA from a "buy" rating to a "hold" rating in a report on Saturday. UBS Group dropped their target price on DENTSPLY SIRONA from $25.00 to $24.00 and set a "buy" rating for the company in a research report on Friday. Needham & Company LLC reiterated a "hold" rating on shares of DENTSPLY SIRONA in a research report on Monday, July 21st. Wells Fargo & Company lowered their price objective on DENTSPLY SIRONA from $16.00 to $15.00 and set an "equal weight" rating for the company in a research report on Friday. Finally, Morgan Stanley downgraded DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 target price for the company. in a report on Tuesday, April 15th. Twelve research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, DENTSPLY SIRONA has an average rating of "Hold" and an average target price of $18.64.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its position in shares of DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock valued at $36,378,000 after buying an additional 2,172,343 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of DENTSPLY SIRONA by 7.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier's stock valued at $8,860,000 after buying an additional 41,579 shares during the last quarter. Cetera Investment Advisers lifted its position in shares of DENTSPLY SIRONA by 27.5% during the 2nd quarter. Cetera Investment Advisers now owns 27,064 shares of the medical instruments supplier's stock valued at $430,000 after buying an additional 5,839 shares during the last quarter. Focus Partners Wealth lifted its holdings in DENTSPLY SIRONA by 59.1% during the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier's stock worth $376,000 after purchasing an additional 9,355 shares in the last quarter. Finally, Empowered Funds LLC lifted its holdings in DENTSPLY SIRONA by 8.8% during the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier's stock worth $244,000 after purchasing an additional 1,320 shares in the last quarter. Institutional investors and hedge funds own 95.70% of the company's stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.